The Confounding Case of Venetoclax in Multiple Myeloma
It is still unclear why patients in the experimental arm in BELLINI saw a worse overall survival (OS) rate than those receiving placebo.
Bone Cancer
BONE CANCER ADVISOR
FEATURED CONTENT
-
-
In-House or Centralized Testing? Debating Whether Genomic Sequencing Is Best Conducted at Home
Genomic analysis of tumors and tests measuring certain biomarkers can be done in-house or sent out. What are the costs and benefits of each approach? -
ctDNA Makes Progress as an Early Treatment Indicator in Breast Cancer
Despite its limitations, ctDNA is emerging as a potentially powerful diagnostic tool. -
What Do Surrogate End Points Actually Predict?
As understanding of cancer improves, drug development could become accelerated, necessitating a means for determining whether a drug is actually effective. -
Enhanced Reimbursement Incentives for Generic Cancer Drugs Found Not to Affect Prescribing Patterns
Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money.
BONE CANCER NEWS
FDA Grants Orphan Drug Designation to BN-Brachyury for Chordoma
CTA Treatment Regimen Chart for Bone Cancer Updated
Baseline EFS Outcomes Identified for Recurrent/Refractory Pediatric Osteosarcoma
In Giant Cell Tumor of Bone, Denosumab Shows Robust Clinical Efficacy
Pacritinib Reduces Spleen Volume in Patients with Myelofibrosis
Want to read more?
Please login or register first to view this content.
Next post in General Oncology
